Field Safety Corrective Actions vs. Recalls: What's the Difference

"Recall" gets used loosely across the medical device industry — in casual conversation, in internal emails, sometimes even in documentation that should be more precise. But in EU regulatory language, "recall" and "Field Safety Corrective Action" are not synonyms, and in US regulatory language, "recall" has a specific legal meaning the FDA assigns after its own review — it isn't a label a manufacturer simply applies to itself. Getting this distinction wrong in documentation, internal communication, or regulatory submissions can create real confusion about what action was actually taken and what obligations follow from it.

Here's how the two systems actually work, where they overlap, and where they genuinely diverge.

What an FSCA Actually Is (EU MDR)

A Field Safety Corrective Action is defined in Article 2(68) of Regulation (EU) 2017/745 (the equivalent definition sits in Article 2(71) of the IVDR) as a corrective action taken by a manufacturer, for technical or medical reasons, to prevent or reduce the risk of a serious incident in relation to a device already made available on the market.

The key thing to understand: FSCA is an umbrella term, not a specific type of action. It covers a range of possible manufacturer responses, including:

• A recall of the device

• A return of the device to the manufacturer or supplier

• A device modification or software update

• Additional inspection or follow-up of patients who received the device

• Changes to labeling or instructions for use

A recall is one specific form an FSCA can take — not a separate category sitting alongside it. As one regulatory source puts it plainly: every recall is an FSCA, but not every FSCA is a recall. If a manufacturer corrects a software issue remotely without physically retrieving any devices, that's an FSCA, but it isn't a recall in the EU sense, because nothing was physically returned from the field.

When an FSCA occurs, the manufacturer must communicate it to users or customers through a Field Safety Notice (FSN) — a formal communication explaining what happened and what action is being taken. This must happen without undue delay once an FSCA is initiated.

What a Recall Actually Is (US FDA)

In US device regulation, the terminology works differently, and the word "recall" carries a more specific, narrower legal weight.

Under 21 CFR 7.3(g), a recall is the correction or removal of a device that violates FDA law, where FDA finds a reasonable probability that the device would cause serious, adverse health consequences or death. Critically, in the US system:

• Correction addresses a problem with a device without physically removing it from where it's used (e.g., an on-site field service repair, a software patch, an updated label).

• Removal refers to physically removing a device from its point of use to another location (for repair, relabeling, destruction, or inspection).

Both corrections and removals must be reported to FDA under 21 CFR Part 806 if they were initiated to reduce a health risk or remedy a legal violation. FDA then reviews the situation and assigns a recall classification — the manufacturer does not self-classify.

FDA Recall Classes

Class I

Reasonable probability that use of, or exposure to, the product will cause serious adverse health consequences or death. The most serious classification.

Class II

May cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote.

Class III

Use of, or exposure to, the product is not likely to cause adverse health consequences.

A nuance worth knowing: recall class and device risk class are entirely different scales, and they can run in opposite directions. A Class III device (highest device risk category, e.g., an implantable cardioverter defibrillator) can still be subject to a Class I recall if the specific defect poses the most severe health risk. Recall classification is about the risk of the specific problem — not the inherent risk category of the device type.

The Core Difference, Side by Side

Legal basis

• EU MDR — FSCA: MDR Article 2(68) / IVDR Article 2(71)

• US FDA — Recall: 21 CFR Parts 7, 806, 810

Scope

• EU MDR — FSCA: An umbrella term covering multiple possible actions — a recall is just one form it can take

• US FDA — Recall: A specific, FDA-assigned classification of a correction or removal

Who decides the type or severity

• EU MDR — FSCA: The manufacturer assesses and initiates; the Competent Authority may review

• US FDA — Recall: FDA itself assigns the classification (Class I, II, or III) after review

Communication mechanism

• EU MDR — FSCA: A Field Safety Notice (FSN)

• US FDA — Recall: Public notification via the FDA recall database, plus direct communication to affected parties

Can it occur without physically retrieving the device?

• EU MDR — FSCA: Yes — a software fix or labeling change can be an FSCA without any device returning from the field

• US FDA — Recall: Yes — a "correction" under 21 CFR 806 doesn't require physical removal either; only "removal" actions involve relocating the device

Public database

• EU MDR — FSCA: EUDAMED (progressively, as the system comes online)

• US FDA — Recall: FDA Medical Device Recalls database / Enforcement Reports

Where the Two Systems Meet

A single underlying device problem can trigger both frameworks simultaneously if the device is sold in both regions. A manufacturer identifying a defect in a device sold in the US and the EU may need to:

• Initiate a recall under 21 CFR Part 7/806 for the US market, with FDA assigning a recall class

• Simultaneously initiate an FSCA under MDR Article 2(68) for the EU market, issuing a Field Safety Notice and notifying the relevant Competent Authority

These aren't two separate problems requiring two separate investigations — they're two regulatory responses to the same root cause, each following its own region's procedural and reporting requirements. A notable cross-border nuance: a US recall for a device also sold in Germany (or elsewhere in the EU) can itself be a reportable FSCA to the relevant EU Competent Authority, even if the underlying cause was identified and acted on first in the US.

Common Points of Confusion

"Every FSCA is a recall." Not true — this is the single most common mix-up. A remote software patch addressing a safety issue is an FSCA under EU MDR but would likely be a "correction" rather than a "recall" in the US system, and may not even require physical device retrieval in either jurisdiction.

"Recall severity and device risk class are the same scale." They're not. A low-risk Class I device can, in principle, trigger any recall class depending on the specific defect — recall classification is about the hazard posed by the specific problem, not a device's baseline risk category.

"The manufacturer decides if something is a 'recall' in the US." In US terms, FDA assigns the recall classification after reviewing the manufacturer's correction or removal action — a manufacturer can voluntarily initiate a correction or removal, but the Class I/II/III designation is FDA's determination, not a self-assigned label.

"FSCA and the US acronym 'MDR' are related." They're not, and the overlapping acronym causes genuine confusion. In EU context, "MDR" means the Medical Device Regulation (2017/745) — the law that defines FSCA. In US device-regulation context, "MDR" means Medical Device Reporting, the adverse-event reporting system under 21 CFR Part 803, which is a related but distinct vigilance mechanism from recalls and corrections.

Why This Distinction Matters in Practice

For regulatory professionals working across both markets, precision here isn't academic:

• Internal documentation and CAPA records should use the terminology that matches the actual regulatory action taken in each jurisdiction, not a generic catch-all term.

• Cross-functional teams (quality, legal, communications) need to understand that an action classified one way in the EU may be communicated differently in the US, even for the identical underlying device issue.

• Post-market surveillance and vigilance reporting timelines differ by jurisdiction and by the specific pathway (FSCA reporting timelines, MDR reportable event timelines, and US correction/removal reporting under 21 CFR 806 each run on their own clocks) — conflating the frameworks risks missing a deadline that applies to one system but not the other.

The Bottom Line

An FSCA is the EU's broad category for manufacturer-initiated field actions addressing device safety risks, communicated via a Field Safety Notice. A recall, in the US sense, is a specific FDA-classified correction or removal action under 21 CFR Parts 7 and 806. A recall is one possible form an FSCA can take — but treating the two terms as interchangeable, or assuming either system's classification logic applies to the other, is a precision error worth correcting in both your documentation and your own understanding.